Insulet PODD Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 71%-0.6pp | 71.6%+0.2pp | 71.5%+0.7pp | 70.7%+0.3pp | 70.4%+0.6pp | |
| Operating margin | 17.5%0.0pp | 17.5%+0.2pp | 17.3%+0.1pp | 17.3%+1.8pp | 15.5%+0.6pp | |
| Net margin | 10.4%+1.3pp | 9.1%-0.6pp | 9.8%-0.2pp | 10%-8.3pp | 18.3%-1.9pp | |
| EBITDA margin | 20.8%-0.1pp | 20.8%0.0pp | 20.8%-0.1pp | 20.9%+1.6pp | 19.3%+0.5pp | |
| Free cash flow margin | 14.3%+0.4pp | 13.9%-2.8pp | 16.8%-0.4pp | 17.2%+3.9pp | 13.2%-1.5pp | |
| Returns | ||||||
| Return on equity | 23%+4.9pp | 18.1%-1.6pp | 19.7%+0.5pp | 19.2%-18.7pp | 37.9%-5.1pp | |
| Return on assets | 9.3%+1.4pp | 7.9%-0.3pp | 8.1%+0.7pp | 7.4%-5.7pp | 13.1%-1.6pp | |
| Return on invested capital | 21%+2.0pp | 19%-2.1pp | 21.2%+1.9pp | 19.3%-1.1pp | 20.4%+2.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×0.0× | 0.9×0.0× | 0.8×+0.1× | 0.7×0.0× | 0.7×0.0× | |
| Inventory turnover | 1.9×+0.1× | 1.7×+0.1× | 1.6×0.0× | 1.6×+0.1× | 1.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.5×-0.3× | 2.8×-0.1× | 2.9×+0.6× | 2.3×-2.2× | 4.5×+0.9× | |
| Quick ratio | 1.8×-0.3× | 2.1×0.0× | 2.2×+0.4× | 1.8×-1.8× | 3.6×+0.9× | |
| Cash ratio | 0.7×-0.4× | 1.1×-0.1× | 1.2×+0.1× | 1.1×-1.4× | 2.5×+0.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.7×+0.1× | 0.7×-0.1× | 0.8×-0.5× | 1.3×-0.1× | 1.3×+0.1× | |
| Debt-to-assets | 0.3×0.0× | 0.3×0.0× | 0.4×-0.2× | 0.5×0.0× | 0.5×0.0× | |
| Net debt / EBITDA | 0.8×+0.3× | 0.5×-0.1× | 0.6×-0.9× | 1.5×+0.3× | 1.2×-0.4× | |
| Interest coverage | 7.8×-0.2× | 8×-0.3× | 8.2×+0.1× | 8.2×-0.1× | 8.3×+1.0× | |
| Per Share | ||||||
| Book value per share | $18.56-12.0% | $21.08+7.6% | $19.59-5.4% | $20.71+15.3% | $17.95+9.5% | |
| Valuation | ||||||
| Market capitalization | $14.77B-26.1% | $20B-8.0% | $21.73B-0.7% | $21.88B+18.6% | $18.44B+0.7% | |
| Enterprise value | $15.26B-24.8% | $20.3B-8.0% | $22.07B-2.4% | $22.62B+19.4% | $18.94B+0.2% | |
| Price / earnings | 48.8×-32.1× | 80.9×-7.4× | 88.3×-4.4× | 92.7×+46.8× | 45.9×+2.1× | |
| Price / sales | 5.1×-2.3× | 7.4×-1.2× | 8.6×-0.7× | 9.3×+0.9× | 8.4×-0.5× | |
| Price / book | 11.3×-1.9× | 13.2×-2.5× | 15.7×+0.7× | 15×+1.1× | 13.9×-1.3× | |
| EV / EBITDA | 25.3×-10.6× | 36×-6.1× | 42.1×-3.7× | 45.8×+1.2× | 44.6×-3.9× | |
| EV / sales | 5.3×-2.2× | 7.5×-1.3× | 8.8×-0.8× | 9.6×+1.0× | 8.6×-0.5× | |
| Free cash flow yield | 2.8%+0.9pp | 1.9%-0.1pp | 1.9%+0.1pp | 1.9%+0.3pp | 1.6%-0.1pp | |
| Earnings yield | 2%+0.8pp | 1.2%+0.1pp | 1.1%+0.1pp | 1.1%-1.1pp | 2.2%-0.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insulet's profit margins?
- Insulet (PODD) runs a 71.0% gross margin and a 17.5% operating margin, with a 10.4% net margin.
- Where do Insulet's ratios come from?
- Every ratio is computed from Insulet's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
